ImaginAb, a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and radiopharmaceuticals (RPT) held its first round table event on December 2nd, 2021.
Entitled 'Imaging may improve decision making in early IO clinical trials', the event was an informative and lively debate with many questions raised and addressed.
A full list of the questions and the responses from our panel of experts, as well as a full recording of the event can be found by clicking on the links below and registering to enter our Knowledge Hub. Once registered, we will send you an email confirming your registration with a link to activate your account. Once activated, you can enter the Knowledge Hub.
If you have any feedback on the event, we'd love to hear it. Please send it to us using this address: [email protected]
The agenda for the first event can be seen below.
If you would like to register for any future round table events that we are planning, then contact us at [email protected]
8.00 – 8.05 am |
Welcome & Introduction |
Ian Wilson |
8.05 – 8.15 am |
BriaCell's partnership with ImaginAb |
William V Williams |
8.15 – 8.55 am |
Q&A session |
Panel |
8.55 – 9.00 am |
Meeting Close |
Ian Wilson |
Since 2016 Dr Williams has headed up BriaCell Therapeutics Corp - developing novel therapies to destroy cancer.
BriaCell and ImaginAb are collaborating to evaluate immunotherapy imaging technology in their current Phase I/IIa study with Incyte in metastatic or locally recurrent breast cancer patients.
CEO of ImaginAb, Ian has over 25 years of experience in development of in vivo medical diagnostics and imaging medical devices. His aspirational vision of growing ImaginAb to transform the healthcare and biotechnology industry has accelerated ImaginAb’s business presence and performance.
Anna is the co-founder and chief scientific advisor to ImaginAb. Among her many titles, Anna is the current co-director, professor and chair of the Department of Molecular Imaging and Therapy, Center for Theranostics within the Diabetes Metabolism Research Institute.
For the past 13 years, Dr. Evelhoch has been responsible for the development and qualification of novel biomarkers, use of biomarkers to inform pipeline decisions and the development and deployment of companion diagnostics at Merck. Dr Evelhoch serves on the Scientific Advisory Board for ImaginAb.
Laura is the Head of Translational Biomarkers at Parthenon Therapeutics, responsible for designing and implementing the company's biomarker strategy across preclinical and clinical activities, including the use of traditional and novel imaging and omics technologies and analysis platforms.
"ImaginAb’s cutting edge CD8 ImmunoPET technology has been used by leading cancer drug developers to more accurately analyze tumors and immune responses to cancer treatments."
